Clinical trial

Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache Following Obstetric Surgery Under Spinal Anesthesia: A Randomized Controlled Trial

Name
FMASU MD 209/2021
Description
Postdural puncture headache (PDPH) is a potential complication after spinal anesthesia caused by traction on pain-sensitive structures from low cerebrospinal fluid pressure (intracranial hypotension) following a leak of cerebrospinal fluid at the puncture site. Symptoms of this condition include a bilateral frontal or occipital headache that is worse in the upright position, along with nausea, neck pain, dizziness, visual changes, tinnitus, hearing loss, or radicular symptoms in the arms. This study will examine the efficacy of mirtazapine in in the treatment of PDPH after obstetric surgery under spinal anesthesia and compared its efficacy with that of sumatriptan.
Trial arms
Trial start
2021-11-15
Estimated PCD
2023-12-20
Trial end
2023-12-20
Status
Completed
Phase
Early phase I
Treatment
Mirtazapine
Mirtazapine 30 mg tablet once daily for 3 successive days
Arms:
Mirtazapine Therapy group (M group)
Sumatriptan
Sumatriptan 50 mg tablet once daily for 3 successive days
Arms:
Sumatriptan Therapy group (S group)
Placebo
Placebo tablets once daily for 3 successive days.
Arms:
Control group ( C group)
Size
210
Primary endpoint
Incidence of refractory headache ((number of patients)(n),% of patients) (refractory: failed intervention and conservative treatment) after 72 hours
72 hours after intervention (Day 0)
Eligibility criteria
Inclusion Criteria: * ASA I and II Patients. * Patients undergoing obstetric surgeries under spinal anesthesia. and complaining from moderate-to-severe PDPH after 25G or 27G spinal needle puncture. Exclusion Criteria: * Refusal of the intervention or participation in the study. * Patient under age of 18 years old. * Psychiatric illness. * Patients with a history of ischemic heart disease, pregnancy-induced hypertension, chronic hypertension, cardiac, vascular, liver or renal impairment. * Patients with a history of migraine. * Patients with known hypersensitivity to study drugs. * Patients currently using ergotamine, monoamine oxidase inhibitors, or selective serotonin reuptake inhibitors.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 210, 'type': 'ACTUAL'}}
Updated at
2024-01-22

1 organization

2 products

1 indication

Indication
headache